Cover Image
市場調查報告書

Pepscan Therapeutics BV : 產品平台分析

Pepscan Therapeutics - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 257868
出版日期 內容資訊 英文 22 Pages
訂單完成後即時交付
價格
Back to Top
Pepscan Therapeutics BV : 產品平台分析 Pepscan Therapeutics - Product Pipeline Review - 2015
出版日期: 2015年09月23日 內容資訊: 英文 22 Pages
簡介

Pepscan Therapeutics BV是Pepscan Holding N.V.的子公司,是正在開發治療癌症及免疫疾病的胜肽及單株抗體的生物製藥公司。該公司提供胜肽合成和重組的胜肽及高通量胜肽程序庫合成等胜肽的廣泛客製服務。同時也提供CLIPS表位製圖。

這份報告提供Pepscan Therapeutics BV的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估及暫停中的計劃等相關資訊。

Pepscan Therapeutics的基本資料

  • Pepscan Therapeutics概要
  • 主要資訊
  • 企業資料

Pepscan Therapeutics BV:R&D概要

  • 主要的治療範圍

Pepscan Therapeutics BV:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Pepscan Therapeutics BV:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

Pepscan Therapeutics BV:藥物簡介

Pepscan Therapeutics BV:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型

Pepscan Therapeutics BV:暫停中的計劃

Pepscan Therapeutics BV:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07607CDB

Summary

Global Markets Direct's, 'Pepscan Therapeutics - Product Pipeline Review - 2015', provides an overview of the Pepscan Therapeutics's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pepscan Therapeutics's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Pepscan Therapeutics including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Pepscan Therapeutics's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Pepscan Therapeutics's pipeline products

Reasons to buy

  • Evaluate Pepscan Therapeutics's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Pepscan Therapeutics in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Pepscan Therapeutics's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Pepscan Therapeutics and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pepscan Therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Pepscan Therapeutics and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Pepscan Therapeutics Snapshot
    • Pepscan Therapeutics Overview
    • Key Information
    • Key Facts
  • Pepscan Therapeutics - Research and Development Overview
    • Key Therapeutic Areas
  • Pepscan Therapeutics - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Pepscan Therapeutics - Pipeline Products Glance
    • Pepscan Therapeutics - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Pepscan Therapeutics - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Pepscan Therapeutics - Drug Profiles
    • hVEGF-26104
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for HIV / AIDS
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Synthetic Peptide for Inflammatory Bowel Disease
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Pepscan Therapeutics - Pipeline Analysis
  • Pepscan Therapeutics - Pipeline Products by Target
  • Pepscan Therapeutics - Pipeline Products by Route of Administration
  • Pepscan Therapeutics - Pipeline Products by Molecule Type
  • Pepscan Therapeutics - Dormant Projects
  • Pepscan Therapeutics - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Pepscan Therapeutics, Key Information
  • Pepscan Therapeutics, Key Facts
  • Pepscan Therapeutics - Pipeline by Indication, 2015
  • Pepscan Therapeutics - Pipeline by Stage of Development, 2015
  • Pepscan Therapeutics - Monotherapy Products in Pipeline, 2015
  • Pepscan Therapeutics - Partnered Products in Pipeline, 2015
  • Pepscan Therapeutics - Partnered Products/ Combination Treatment Modalities, 2015
  • Pepscan Therapeutics - Phase I, 2015
  • Pepscan Therapeutics - Discovery, 2015
  • Pepscan Therapeutics - Pipeline by Target, 2015
  • Pepscan Therapeutics - Pipeline by Route of Administration, 2015
  • Pepscan Therapeutics - Pipeline by Molecule Type, 2015
  • Pepscan Therapeutics - Dormant Developmental Projects,2015

List of Figures

  • Pepscan Therapeutics - Pipeline by Top 10 Indication, 2015
  • Pepscan Therapeutics - Pipeline by Stage of Development, 2015
  • Pepscan Therapeutics - Monotherapy Products in Pipeline, 2015
  • Pepscan Therapeutics - Partnered Products in Pipeline, 2015
  • Pepscan Therapeutics - Pipeline by Top 10 Molecule Type, 2015
Back to Top